Table 1. Correlations between the miRNA expression levels and the clinicopathological variables in patients with DLBCL.
| Variablesa | miR-21 | miR-17-92 cluster | miR-155 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| All (n = 200) | Low (n = 162) | High (n = 38) | P | Low (n = 126) | High (n = 74) | P | Low (n = 121) | High (n = 79) | P | |
| Age | ||||||||||
| Mean (range) | 58.1(8-86) | 57.56(8-86) | 60.58(12-85) | 0.271 | 56.2(8-86) | 61.4(12-85) | 0.019 | 55.72(8-86) | 61.84(23-85) | 0.003 |
| <60 | 90 | 76(84.4%) | 14(15.6%) | 0.261 | 63(70.0%) | 27(30.0%) | 0.064 | 63(70.0%) | 27(30.0%) | 0.013 |
| ≥60 | 110 | 86(78.2%) | 24(21.8%) | 63(57.3%) | 47(42.7%) | 58(52.7%) | 52(47.3%) | |||
| Sex | ||||||||||
| Male | 113 | 92(81.4%) | 21(18.6%) | 0.864 | 78(69.0%) | 35(31.0%) | 0.044 | 71(62.8%) | 42(37.2%) | 0.442 |
| Female | 87 | 70(80.5%) | 17(19.5%) | 48(55.2%) | 39(44.8%) | 50(57.5%) | 37(42.5%) | |||
| Primary Site | ||||||||||
| Nodal | 61 | 47(77.0%) | 14(23.0%) | 0.345 | 39(63.9%) | 22(36.1%) | 0.856 | 31(50.8%) | 30(49.2%) | 0.064 |
| Extranodal | 139 | 115(82.7%) | 24(17.8%) | 87(62.6%) | 52(37.4%) | 90(64.7%) | 49(35.3%) | |||
| Stage | ||||||||||
| 1,2 | 107 | 93(86.9%) | 14(13.1%) | 0.011 | 72(67.3%) | 35(32.7%) | 0.117 | 72(67.3%) | 35(32.7%) | 0.018 |
| 3,4 | 87 | 63(72.4%) | 24(27.6%) | 49(56.3%) | 38(43.7%) | 44(50.6%) | 43(49.4%) | |||
| R-IPI group | ||||||||||
| Very good + Good | 114 | 96(84.2%) | 18(15.8%) | 0.120 | 75(65.8%) | 39(34.2%) | 0.179 | 75(65.8%) | 39(34.2%) | 0.031 |
| Poor | 63 | 47(74.6%) | 16(25.4%) | 35(55.6%) | 28(44.4%) | 31(49.2%) | 32(50.8%) | |||
| B symptom | ||||||||||
| Absent | 159 | 131(82.4%) | 28(17.6%) | 0.139 | 98(61.6%) | 61(38.4%) | 0.652 | 102(64.2%) | 57(35.8%) | 0.003 |
| Present | 35 | 25(71.4%) | 10(28.6%) | 23(65.7%) | 12(34.3%) | 13(37.1%) | 22(62.9%) | |||
| Bulky | ||||||||||
| Absent | 174 | 141(81.0%) | 33(19.0%) | 0.597 | 107(61.5%) | 67(38.5%) | 0.374 | 107(61.5%) | 67(38.5%) | 0.100 |
| Present | 21 | 16(76.2%) | 5(23.8%) | 15(71.4%) | 6(28.6%) | 9(42.9%) | 12(57.1%) | |||
| Performance status | ||||||||||
| 0-1 | 146 | 120(82.2%) | 26(17.8%) | 0.247 | 98(67.1%) | 48(32.9%) | 0.012 | 92(63.0%) | 54(37.0%) | 0.049 |
| ≥2 | 47 | 35(74.5%) | 12(25.5%) | 22(46.8%) | 25(53.2%) | 22(46.8%) | 25(53.2%) | |||
| Serum LDH | ||||||||||
| Normal | 77 | 65(84.4%) | 12(15.6%) | 0.295 | 48(62.3%) | 29(37.7%) | 0.983 | 50(64.9%) | 27(35.1%) | 0.246 |
| Elevated | 96 | 75(78.1%) | 21(21.9%) | 60(62.5%) | 36(37.5%) | 54(56.2%) | 42(43.8%) | |||
| Extranodal sites (n) | ||||||||||
| 0.1 | 153 | 126(82.4%) | 27(17.6%) | 0.163 | 98(64.1%) | 55(35.9%) | 0.293 | 93(60.8%) | 60(39.2%) | 0.507 |
| ≥2 | 40 | 29(72.5%) | 11(27.5%) | 22(55.0%) | 18(45.0%) | 22(55.0%) | 18(45.0%) | |||
| Bone marrow involvement | ||||||||||
| Absent | 154 | 125(81.2%) | 29(18.8%) | 0.546 | 96(62.3%) | 58(37.7%) | 0.873 | 90(58.4%) | 64(41.6%) | 0.600 |
| Present | 25 | 19(76.0%) | 6(24.0%) | 16(64.0%) | 9(36.0%) | 16(64.0%) | 9(36.0%) | |||
| Rituximab treatment | ||||||||||
| No | 91 | 68(74.7%) | 23(25.3%) | 0.052 | 57(62.6%) | 34(37.4%) | 0.975 | 55(60.4%) | 36(39.6%) | 0.843 |
| Yes | 105 | 90(85.7%) | 15(14.3%) | 66(62.9%) | 39(37.1%) | 62(59.0%) | 43(41.0%) | |||
| GCB vs. ABC (Choi) | ||||||||||
| GCB | 53 | 45(84.9%) | 8(15.1%) | 1.000 | 36(67.9%) | 17(32.1%) | 0.743 | 38(71.7%) | 15(28.3%) | 0.043 |
| ABC | 95 | 79(83.2%) | 16(16.8%) | 62(65.3%) | 33(34.7%) | 52(54.7%) | 43(45.3%) | |||
R-IPI, revised-international prognostic index; GCB, germinal center B cell-like; ABC, activated B-cell like
a
Several variables contain missing values due to the lack of relevant information in the patients.